Physician profile
Juan Ivan Ramirez
NPI 1205835071
$2,168.67
in general payments reported to CMS, 2019-2025
15 companies · $22.59 in 2025
The $22.59 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $397 · 2021: $399 · 2022: $187 · 2023: $199 · 2024: $41.04 · 2025: $22.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,055.72 | 2019-2022 | |
| Allergan, INC. | $382.36 | 2019-2021 | |
| Abbvie INC. | $231.75 | 2020-2024 | |
| Novo Nordisk INC | $116.21 | 2023-2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $95.89 | 2019-2021 | |
| Boston Scientific Corporation | $79.23 | 2023 | |
| Mylan Specialty L.P. | $58.32 | 2020 | |
| Portola Pharmaceuticals, LLC | $34.64 | 2019 | |
| Horizon Therapeutics Plc | $24.92 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.81 | 2024 | |
| Astellas Pharma US INC | $15.46 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.41 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.67 | 2022 | |
| Csl Behring | $12.50 | 2019 | |
| Therapeuticsmd, INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.